Top 5 Emergency Medicine Apps for Primary Care Providers

December 11th 2025

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

Flow Therapeutics announced approval of its Flow-100 tDCS therapy for depression, which could expand access to non-pharmacologic care and will be available in the US in H2 2026.

November 19th 2025

Agitation in Alzheimer Disease: Proactive Assessment and Caregivers' Roles with Carolyn Clevenger, GNP

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

Carolyn Clevenger, GNP;Grace Halsey

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Clevenger speaks to primary care clinicians, emphasizing 3 priorities: engage family as partners, ask about agitation, and recognize its danger to patient and caregiver.

November 13th 2025

Weekly Dose Podcast: New AD Blood Test, Elinzanetant’s Sleep Effects, Lung Cancer Screening Success, Menopause Symptom Burden, and VMS Treatment Approval

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

Genetic Evidence Supports a Causal Link Between Psoriasis and Depression

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

FDA Clears First At-Home Brain-Stimulation Device for Major Depression

Genetic predisposition to psoriasis appears to raise depression risk, offering insights into shared inflammatory mechanisms and implications for screening.

Related Content

December 11th 2025

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

Flow Therapeutics announced approval of its Flow-100 tDCS therapy for depression, which could expand access to non-pharmacologic care and will be available in the US in H2 2026.

November 19th 2025

Agitation in Alzheimer Disease: Proactive Assessment and Caregivers' Roles with Carolyn Clevenger, GNP

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

Carolyn Clevenger, GNP;Grace Halsey

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Clevenger speaks to primary care clinicians, emphasizing 3 priorities: engage family as partners, ask about agitation, and recognize its danger to patient and caregiver.

November 13th 2025

Weekly Dose Podcast: New AD Blood Test, Elinzanetant’s Sleep Effects, Lung Cancer Screening Success, Menopause Symptom Burden, and VMS Treatment Approval

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

Genetic Evidence Supports a Causal Link Between Psoriasis and Depression

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.